- TEVA stock is down irrationally after its quarterly earnings report.
- Shares traded at a 2021 forward P/E in the 3 times range.
- Outlook reaffirmed.
For further details see:
Five Considerations After Teva Pharmaceuticals' Q3 ReportFor further details see:
Five Considerations After Teva Pharmaceuticals' Q3 ReportMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
NASDAQ Market:
Cassava Sciences Inc. Website:
Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, if they desire, pending results of the ongoing pivotal Phase 3 trials. ...